Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Kim N. et al.|The Lancet|2017Cited by 177
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Siobhan Ng, Ronald de Wit et al.|The Lancet Oncology|2019Cited by 87
Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignanciesMichael A. Morse, H. Kim Lyerly, Timothy Clay et al.|Journal of Clinical Oncology|2004Cited by 13
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Marion van Mackelenbergh, Eva Ciruelos et al.|Nature Medicine|2024Cited by 8
Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignanciesMichael Morse, H. Kim Lyerly, Timothy Clay et al.|Journal of Clinical Oncology|2004Cited by 4